SGP.US SpyGlass Pharma, Inc.
- Market cap
- USD 1.05B
- P/E
- -
- P/B
- 5.11x
- ROE
- -36.7%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is SGP.US undervalued?
Graham numberThe Graham number of SpyGlass Pharma, Inc. cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
SpyGlass Pharma, Inc. fundamental analysis
No fundamental analysis for SpyGlass Pharma, Inc. yet.
SpyGlass Pharma, Inc. stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About SpyGlass Pharma, Inc.
SpyGlass Pharma, Inc. operates as a biopharmaceutical company that provides treatment and drug delivery for patients living with chronic eye conditions. The company develops the Bimatoprost Drug Pad-IOL System (BIM-IOL System), including novel and proprietary drug pads attached to an intraocular lens (IOL), which is designed to be implanted during routine cataract surgery to reduce elevated intraocular pressure (IOP) in patients. It also develops a non-IOL-based, ring-shaped…
Full company profileSpyGlass Pharma, Inc. financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
SpyGlass Pharma, Inc. annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|
| Income Statement | ||||
| Revenue | 0.00 | 0.00 | 0.00 | - |
| Gross Profit | - | - | -612K | -1.25M |
| Operating Income | -14.2M | -27.1M | -41.4M | -84.8M |
| EBITDA | -14.1M | -26.8M | -39.3M | -81.5M |
| Net Income | -13.3M | -29.2M | -39.9M | -77.2M |
| EPS | -0.42 | -0.91 | -1.25 | -2.31 |
| Balance Sheet | ||||
| Total Assets | 41.1M | 23.3M | 116M | 226M |
| Total Liabilities | 74.1M | 83.8M | 215M | 15.9M |
| Shareholders' Equity | -33.0M | -60.5M | -98.8M | 210M |
| Cash & Short-term Investments | 15.8M | 16.3M | 107M | 216M |
| Total Debt | - | - | 1.58M | 1.61M |
| Cash Flow | ||||
| Operating Cash Flow | -12.3M | -22.0M | -32.7M | -59.2M |
| Capital Expenditure | 217K | 1.99M | 789K | 6.76M |
| Free Cash Flow | -12.5M | -24.0M | -33.5M | -66.0M |
| Ratios | ||||
| ROE | - | - | - | -36.7% |
| ROA | -32.4% | -125.1% | -34.4% | -34.1% |
| Debt to Equity | - | - | - | 0.01x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Debt to Equity
- Total debt divided by shareholders' equity.
SpyGlass Pharma, Inc. dividends
SpyGlass Pharma, Inc. has not paid dividends in the last 3 fiscal years.
Who owns SpyGlass Pharma, Inc.
- Insiders 4.27%
- Institutions 95.36%
- Public & others 0.37%
- Shares outstanding 33.5M
- Free float 6.51M
Top funds holding SGP.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Vanguard MStar Total Stk Mkt Idx Invest | 561K | 1.68% | +76.88% | Sep 2026 |
| JPMorgan Small Cap Growth A | 461K | 1.38% | -0.61% | Sep 2026 |
| abrdn Healthcare Investors | 222K | 0.66% | 0.00% | Oct 2026 |
| T. Rowe Price New Horizons | 186K | 0.56% | -11.03% | Sep 2026 |
| JPMorgan Small Cap Blend A | 146K | 0.44% | -1.63% | Sep 2026 |
| abrdn Healthcare Opportunities | 135K | 0.40% | 0.00% | Sep 2026 |
| Fidelity Small Cap Index | 121K | 0.36% | 0.00% | Aug 2026 |
| abrdn World Healthcare | 108K | 0.32% | 0.00% | Sep 2026 |
| Franklin Biotechnology Discovery A | 84.7K | 0.25% | 0.00% | Sep 2026 |
| Vanguard Russell 2000 ETF | 53.8K | 0.16% | -15.53% | Sep 2026 |
| JPM US Small Cap Growth A dist USD | 51.3K | 0.15% | -1.62% | Sep 2026 |
| ALPS Medical Breakthroughs ETF | 40.9K | 0.12% | 0.00% | Oct 2026 |
| abrdn Life Sciences Investors | 40.8K | 0.12% | 0.00% | Oct 2026 |
| Schwab US Small-Cap ETF™ | 35.4K | 0.11% | +0.18% | Oct 2026 |
| Fidelity Extended Market Index | 34.2K | 0.10% | -31.12% | Sep 2026 |
| JPM US Small Cap Growth C Acc | 33.7K | 0.10% | -4.29% | Sep 2026 |
| TD Health Sciences - I | 23.8K | 0.07% | 0.00% | Jun 2026 |
| JPMorgan American Ord | 23.6K | 0.07% | 0.00% | Aug 2026 |
| Schwab Small Cap Index | 22.5K | 0.07% | -16.16% | Sep 2026 |
| Fidelity Nasdaq Composite Index | 20.9K | 0.06% | 0.00% | Aug 2026 |
Top institutions holding SGP.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| RA Capital Management, LLC | 8.02M | 23.97% | 0.00% | Jun 2026 |
| NEA Management Company, LLC | 7.39M | 22.09% | 0.00% | Jun 2026 |
| Sands Capital Ventures, LLC | 2.50M | 7.47% | 0.00% | Sep 2026 |
| Samsara BioCapital, LLC | 2.11M | 6.31% | 0.00% | Jun 2026 |
| BlackRock Inc | 712K | 2.13% | +391.72% | Jun 2026 |
| T. Rowe Price Associates, Inc. | 674K | 2.01% | -4.30% | Jun 2026 |
| Vestal Point Capital LP | 670K | 2.00% | +0.49% | Jun 2026 |
| JPMorgan Chase & Co | 630K | 1.88% | +9.12% | Jun 2026 |
| Deerfield Management Co | 550K | 1.64% | 0.00% | Jun 2026 |
| Millennium Management LLC | 507K | 1.52% | +8.20% | Jun 2026 |
| Aberdeen Group PLC | 507K | 1.51% | +2.72% | Sep 2026 |
| Vanguard Capital Management, LLC | 434K | 1.30% | -0.09% | Jun 2026 |
| Geode Capital Management, LLC | 277K | 0.83% | +119.16% | Jun 2026 |
| Franklin Templeton Inc | 233K | 0.70% | -22.20% | Jun 2026 |
| Affinity Asset Advisors, LLC | 132K | 0.39% | -47.37% | Jun 2026 |
| State Street Corp | 118K | 0.35% | +581.51% | Jun 2026 |
| Charles Schwab Investment Management Inc | 85.7K | 0.26% | +43.74% | Jun 2026 |
| Northern Trust Corp | 82.5K | 0.25% | +295.22% | Jun 2026 |
| Vanguard Portfolio Management, LLC | 75.8K | 0.23% | +1,960.11% | Jun 2026 |
| Vanguard Fiduciary Trust Co | 68.5K | 0.20% | +14.58% | Jun 2026 |
SpyGlass Pharma, Inc. company profile
- Company name
- SpyGlass Pharma, Inc.
- Ticker
- SGP.US
- Exchange
- USA Stocks
- Listed since
- Feb 6, 2026
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 88
- Fiscal year end
- December
- Address
- 15326 Alton Parkway, Irvine, CA, United States, 92618
- Phone
- 949 284 6904
- Website
- spyglasspharma.com
About SpyGlass Pharma, Inc.
SpyGlass Pharma, Inc. operates as a biopharmaceutical company that provides treatment and drug delivery for patients living with chronic eye conditions. The company develops the Bimatoprost Drug Pad-IOL System (BIM-IOL System), including novel and proprietary drug pads attached to an intraocular lens (IOL), which is designed to be implanted during routine cataract surgery to reduce elevated intraocular pressure (IOP) in patients. It also develops a non-IOL-based, ring-shaped, sustained-release implant with bimatoprost. SpyGlass Pharma, Inc. was formerly known as SpyGlass Ophthalmics, Inc. and changed its name to SpyGlass Pharma, Inc. in April 2021. The company was headquartered in 2019 and is based in Irvine, California.
SpyGlass Pharma, Inc. management
10- Dr. Malik Y. Kahook M.D.Co-Founder, President, Chief Medical Officer & Executive Chairman · born 1975
- Mr. Patrick H. MooneyCEO & Director · born 1974
- Dr. Chetan Pujara Ph.D.Chief Research & Development Officer · born 1970
- Mr. Glenn SussmanCo-founder & Chief Technology Advisor · born 1964
- Dr. Jean-Frederic Viret Ph.D.Chief Financial Officer · born 1966
- Mr. James Robert Dennewill Jr.Chief Operating Officer · born 1981
- Ms. Shannon Trevino J.D.General Counsel
- Mr. Mike PinderVice President of Marketing
- Ms. Rachel GiletteVice President of Human Resources
- Mr. Paul Yoo O.D.Senior Vice President of Clinical Development